NewAmsterdam Pharma saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 77 to 81.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
History shows that the best-performing stocks often have an RS Rating of at least 80 in the early stages of their moves.
NewAmsterdam Pharma is working on a consolidation with a 27.29 buy point. See if it can break out in heavy trade.
The company posted 0% EPS growth last quarter. Revenue increased 113%.
NewAmsterdam Pharma earns the No. 119 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
